Towards Healthcare

News

Your Daily Gateway to Essential News in Healthcare, Science, Technology and Business Worldwide

TYBR Health’s new gel formulation to heal post-surgical wounds
08 January 2026

TYBR Health’s new gel formulation to heal post-surgical wounds

Announcement TYBR Health is a known Houston-related regenerative medicine and medical technology company popular for its establishment in biomaterials therapies to refine post-operative recovery. The company has introduced the first-ever U.S. clinical use of the B3 GEL™ System. Regarding this...

GenEditBio’s Application went on another desk for the TGFBI Corneal Dystrophy
08 January 2026

GenEditBio’s Application went on another desk for the TGFBI Corneal Dystrophy

Announcement GenEditBio stepped into the biotech competition in 2021 with one goal and mission in mind to serve vivo genome-editing therapeutic solutions. The company now excitedly declared that its IND (Investigational New Drug) application has received a clean chit by the U.S. Food and Drug Admin...

Novo to count profit on one gulp with its new Wegovy™ Pill launch
08 January 2026

Novo to count profit on one gulp with its new Wegovy™ Pill launch

Announcement Novo Nordisk, the promising Danish healthcare organisation known for its excellent progress in diabetes care and later splitting its business and excellence in rare blood disorders, growth hormone therapies and obesity. The company has now launched Wegovy™ pill to be registered i...

Takeda’s seriousness towards Trial Representation to revolutionise the Clinical Research sector
08 January 2026

Takeda’s seriousness towards Trial Representation to revolutionise the Clinical Research sector

Announcement Takeda, with a strong footprint in Europe, Japan, and the US, and popularly recognised for its Entyvio for IBD, as Asia’s third-largest pharmaceutical company, shed some light on the trial representation. Takeda raises awareness and value for its patients regarding the company&rs...

BioAtla and GATC initiate SPV transaction to bolster the ongoing study
06 January 2026

BioAtla and GATC initiate SPV transaction to bolster the ongoing study

Announcement BioAtla, Inc., a leading clinical-level biotechnology company focusing on the establishment of Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has joined hands with GATC Health Corp. (GATC). GATC is a well-known tech-bio company accelerating artific...

Axsome receives clearance to NDA filing for AXS-05 and Priority Review designation
06 January 2026

Axsome receives clearance to NDA filing for AXS-05 and Priority Review designation

Announcement Axsome Therapeutics, Inc., a leading biopharmaceutical company revolutionising the treatment space of central nervous system (CNS) disorders, received acceptance from the U.S. Food and Drug Administration (FDA) for its filing of the supplemental New Drug Application (NDA) for AXS-05 (b...

Intelligent and Syrma entered a manufacturing partnership agreement
06 January 2026

Intelligent and Syrma entered a manufacturing partnership agreement

Announcement Intelligent Bio Solutions Inc., a leading medical technology company serving an emerging, non-invasive brilliant testing solutions, have inked a manufacturing deal with Syrma Johari MedTech Ltd. Syrma is a known well recognized medical device manufacturing and engineering company with ...

XORTX’s Research and business update to accelerate growth
06 January 2026

XORTX’s Research and business update to accelerate growth

Announcement XORTX Therapeutics Inc., a leading late-stage clinical pharmaceutical company aiming to establish innovative therapies for the treatment of progressive kidney and gout diseases, unveiled the latest independent peer-reviewed published research reports. The reports that extend recent inf...

Cogent enveloped its application to the FDA
05 January 2026

Cogent enveloped its application to the FDA

Announcement Cogent Biosciences, Inc., a leading biotechnology company dedicated to establishing accurate therapies for genetically defined diseases, has now submitted its promising New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company’s best-in-class bezuc...

Tiger BioSciences’ recap of 2025’s major milestones
05 January 2026

Tiger BioSciences’ recap of 2025’s major milestones

Recap Tiger BioSciences spotlights the number of important and valuable scientific and clinical advances that have been made from the company’s extensive investment in proof-based research across this year. This smart and rock-built strategy target has bolstered the company’s position a...